Lidokain Galenpharma (Lidocaine)

Lidokain Galenpharma, a lidocaine‑based local anesthetic, is used to numb the rectal area for various clinical situations.

• Rectal procedures: provides localized anesthesia to facilitate diagnostic or therapeutic interventions with minimal discomfort.
• Hemorrhoidal pain: reduces acute pain associated with hemorrhoids, allowing patients to tolerate daily activities.
• Anal fissure pain: alleviates discomfort during bowel movements in patients with anal fissures.
• Proctologic surgery: offers intra‑operative analgesia to improve surgical conditions and patient comfort.

• Lidocaine exerts its anesthetic effect by reversibly blocking voltage‑gated sodium channels on neuronal membranes. This inhibition prevents the initiation and propagation of action potentials, thereby halting nerve impulse transmission in the targeted area. The result is a rapid onset of loss of sensation localized to the site of application, and relatively short, with a duration that depends on dose and tissue perfusion.

Lidokain Galenpharma may be associated with adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Mild burning sensation at the application site lasting a few minutes
• Transient numbness that may spread slightly beyond the treated area
• Local itching or erythema that resolves spontaneously
• Mild headache occurring shortly after administration

Serious or Rare Side Effects

• Allergic reaction such as rash, facial swelling, or anaphylaxis requiring emergency care
• Cardiac arrhythmias, including bradycardia or tachycardia, especially with high systemic absorption
• Central nervous system toxicity manifesting as seizures or profound drowsiness
• Methemoglobinemia, a rare blood disorder that reduces oxygen‑carrying capacity

When using Lidokain Galenpharma, several precautions should be observed to minimize risk and ensure safe administration.

• Assess allergy: confirm no known hypersensitivity to lidocaine or amide‑type anesthetics.
• Cardiac considerations: use cautiously in patients with conduction disorders or severe heart disease.
• Dose limitation: adhere strictly to the prescriber’s recommended amount to avoid systemic toxicity.
• Monitor toxicity: watch for signs such as dizziness, tinnitus, or altered mental status during and after use.
• Pregnancy and lactation: evaluate risk‑benefit ratio and consider alternative therapies when possible.
• Store at room temperature: keep in the original container, protect from moisture and direct light.

Lidokain Galenpharma can interact with other medicines; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine plasma concentrations and toxicity.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise systemic levels of lidocaine.
• Concurrent use of other amide local anesthetics (e.g., bupivacaine): additive nerve‑blockade may lead to overdose.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance lidocaine’s cardiac depressant effects, requiring ECG monitoring.
• Loop diuretics: can alter plasma protein binding, potentially increasing free lidocaine.
• General anesthetics (e.g., propofol, inhalational agents): may potentiate central nervous system depression when combined.